Holen Sie sich die Stockscreener-App
4.59
0.88%
0.04
Lisata Therapeutics Inc Aktie (LSTA) Neueste Nachrichten
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - stocktitan.net
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva - The Globe and Mail
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Nigeria
Lisata Therapeutics Signs Binding Term Sheet With Kuva Labs - TradingView
Lisata To Be Acquired By Kuva Labs For $4/shr; Stock Soars Over 80% - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs for $4 per Share - intellectia.ai
Lisata Therapeutics (LSTA) Agrees to Acquisition by Kuva Labs - GuruFocus
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer - marketscreener.com
Lisata Therapeutics Enters Binding Agreement for Acquisition by Kuva Labs with Significant Premium for Stockholders - Quiver Quantitative
Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com
Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView
Lisata Therapeutics Enters Into Term Sheet to be Acquired - GlobeNewswire
0.47%
2.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):